Tailor Bio
Tailor Bio is a Cambridge, UK-based precision oncology techbio that uses proprietary AI-driven chromosomal instability (CIN) signature algorithms to predict chemotherapy resistance, develop companion diagnostics, and identify synthetic lethal drug targets across multiple cancer types, serving pharmaceutical partners and ultimately health systems.
- Company typePrivate
- Founded2019
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Tailor Bio does
Tailor Bio is a Cambridge, UK-based precision oncology techbio founded in 2019 and spun out of the Cancer Research UK Cambridge Institute. The company has built an AI-driven pan-cancer precision medicine platform whose core technology is a set of proprietary chromosomal instability (CIN) signature algorithms. These algorithms decode the complexity of CIN — a genomic phenomenon present in 80% of human cancers and associated with aggressive, treatment-resistant disease — in order to identify synthetic lethal therapeutic strategies, predict chemotherapy response, and stratify patients for targeted therapies. The platform is multi-modal, compatible with whole-genome sequencing, targeted panels, and cell-free (blood-derived) DNA, and has been validated across 840 real-world patients in ovarian, breast, prostate, and sarcoma cancers, with predicted-resistant patients shown to be up to seven times more likely to experience treatment failure. Founded on research co-developed with the Spanish National Cancer Research Centre (CNIO), the company is led by Dr Geoff Macintyre (CSO) and Jason Yip (CEO), with scientific advisory input from Sir Steve Jackson (PARP inhibitor pioneer).
The company's commercial product surface centres on a modular pipeline of 3 therapeutic programs and 2 biomarker programs, supported by 2 proprietary IP assets and 1 in-licensing opportunity, and includes a CIN Test / CIN Biomarker Diagnostic and a Doxorubicin Response Diagnostic for high-grade serous ovarian cancer. Tailor Bio monetises primarily through B2B licensing and co-development partnerships with pharmaceutical and biotech companies (e.g., the Volastra Therapeutics collaboration for KIF18A inhibitors), companion diagnostic licensing for clinical-trial patient stratification, and future clinical-test deployment through health-system laboratory partnerships. The GTM motion is enterprise field sales, targeting oncology drug developers seeking biomarker-driven patient selection and health systems adopting precision chemotherapy. Sales channels include direct enterprise engagement, the Illumina TruSight Oncology CE-IVD-compatible assay pathway (via the partnership with Illumina), and content-led credibility built on top-tier publications, scientific conferences, and PR.
To date, the company has secured approximately £2.65M in non-dilutive and dilutive funding — a £650K Innovate UK Biomedical Catalyst grant in 2022, a £2M seed round led by Ascension Life Fund in February 2023, and seed-stage support through the Illumina Accelerator program in 2020. The team remains small (1-10 employees), the operating geography is concentrated in the UK/Europe, and the platform is pre-commercial, with prospective clinical trials for the lead CIN test scheduled for 2026.
Tailor Bio firmographics
Firmographics- Name
- Tailor Bio
- Legal name
- Tailor Bio Ltd
- Website
- https://tailor.bio
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Tailor Bio is a Cambridge, UK-based precision oncology techbio that uses proprietary AI-driven chromosomal instability (CIN) signature algorithms to predict chemotherapy resistance, develop companion diagnostics, and identify synthetic lethal drug targets across multiple cancer types, serving pharmaceutical partners and ultimately health systems.
- Ownership category
- akta.pro rank
Tailor Bio industry classification
Industry- Product category
- Precision Oncology Platforms
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Tailor Bio is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Tailor Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Companion Diagnostic Licensing & Partnerships: Tailor Bio licenses its CIN diagnostic platform to pharmaceutical partners for patient stratification in clinical trials, enabling targeted drug development for CIN-driven cancers. The company also develops companion diagnostics for specific therapeutics (e.g., doxorubicin response prediction in ovarian cancer).
- Therapeutic Drug Discovery Platform: Tailor Bio leverages its pan-cancer CIN platform to identify new therapeutic targets for drug development, generating value through co-development partnerships with pharmaceutical companies and potential out-licensing of discovered targets or compounds.
- Clinical CIN Test Deployment: The company is advancing its CIN test through analytical validation and prospective trials (2026), positioning for clinical adoption across health systems for chemotherapy personalisation, likely through test-as-a-service or laboratory licensing models.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Tailor Bio product offering
Product offeringCore offering
Tailor Bio operates an AI-driven pan-cancer precision medicine platform built on proprietary chromosomal instability (CIN) signature algorithms that decode CIN complexity to identify synthetic lethal therapeutic targets and predict chemotherapy response. The company develops companion diagnostics for patient stratification and advances therapeutic programs targeting CIN-driven cancers across multiple tumor types from a single genomic test compatible with whole-genome sequencing, targeted panels, and cell-free DNA.
Product overview
Tailor Bio is a techbio precision oncology company operating a modular platform architecture comprising its AI-driven Pan-Cancer Precision Medicine Platform as the core technology, supplemented by specific diagnostic products including the CIN Test/CIN Biomarker Diagnostic for predicting chemotherapy response and the Doxorubicin Response Diagnostic for ovarian cancer. The company advances drug discovery through Therapeutic Programs (3 programs) and companion diagnostics through Biomarker Programs (2 programs), all built on proprietary CIN signature analysis. The platform enables simultaneous drug discovery and companion diagnostics development across multiple cancer types.
Differentiator
Problem solved
Functional benefit
Products and services
- Pan-Cancer Precision Medicine Platform AI-driven modular platform that identifies therapeutic targets and improves patient stratification for cancers with chromosomal instability, integrating proprietary CIN signature algorithms with multi-modal analysis across whole-genome sequencing, targeted panels, and cell-free DNA. Built for pharmaceutical partners and oncology drug developers.
- CIN Test / CIN Biomarker Diagnostic Companion diagnostic designed for clinical adoption that uses CIN signatures to predict chemotherapy response and identify patients unlikely to respond to platinum-, taxane-, and anthracycline-based treatments from a single genomic test compatible with blood-derived DNA.
- Doxorubicin Response Diagnostic Predictive diagnostic identifying high-grade serous ovarian cancer patients who will not respond to doxorubicin chemotherapy, with compatibility assessed against the Illumina TruSight Oncology Comprehensive assay.
- Therapeutic Programs Drug development programs targeting CIN-driven cancers using synthetic lethal strategies identified through the CIN signature platform, encompassing 3 therapeutic programs with proprietary compound IP available for co-development and out-licensing with pharmaceutical partners.
- Biomarker Programs Companion diagnostics development programs that leverage CIN signatures for patient stratification across multiple cancer types, encompassing 2 biomarker programs with proprietary IP assets.
Quantifiable outcome
- Patients predicted to be resistant were up to seven times more likely to experience treatment failure across 840 patients with ovarian, breast, prostate, and sarcoma cancers.
- +1 more outcomes
Companies that use Tailor Bio
Customer profileSegments3 records
Ideal customer profiles2 records
Tailor Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Tailor Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core research partner, core partnership and key platform partner.
- University of Cambridgecore research partnerCollaborated on a pivotal study demonstrating the power of CIN signatures to predict chemotherapy resistance across multiple cancer types. The study used Tailor Bio's novel CIN biomarker platform on real-world clinical data. The company was spun out of the Cancer Research UK Cambridge Institute at the University.
- Spanish National Cancer Research Centre (CNIO)core research partnerCollaborated with Tailor Bio on the pivotal study validating CIN biomarker predictive power for chemotherapy resistance. Scientific co-founder Dr Geoff Macintyre originated from CNIO, and key patents are licensed from this institution.
- Volastra Therapeuticscore partnershipCollaboration to advance the development of targeted therapies for cancer by broadening the potential of KIF18A inhibitors through identification of predictive biomarkers. Tailor Bio applies its CIN signature biomarker expertise to quantify chromosomal instability and define patient subsets most likely to respond to treatment across a wide range of tumour types.
- Illuminakey platform partnerCollaborating with Tailor Bio on developing a diagnostic for ovarian cancer and assessing compatibility of Tailor's platform with the Illumina TruSight Oncology Comprehensive assay which has CE-IVD marking in Europe. Illumina also provides platform access as part of the Illumina Accelerator program.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Tailor Bio competitors and assessment
Company assessmentBroad incumbents
- Caris Life Sciences: Caris provides molecular profiling and AI-driven precision oncology solutions across DNA, RNA, and protein analysis. Comparable to Tailor Bio as an AI-enabled multi-modal platform delivering patient stratification for oncology therapy selection.
- Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company offering blood-based genomic tests. Comparable to Tailor Bio's CIN test compatibility with cell-free DNA from blood-derived samples and the broader companion diagnostics GTM motion.
- Foundation Medicine: Foundation Medicine is a leading molecular profiling company offering comprehensive genomic profiling tests for oncology treatment selection. Comparable to Tailor Bio as a genomic-profiling-driven oncology diagnostics provider informing therapy choice.
- Tempus AI: Tempus AI combines genomic sequencing with AI/ML models to support precision oncology decisions for clinicians and pharma partners. Comparable to Tailor Bio as an AI-driven oncology platform leveraging genomic data to inform treatment selection and partner with pharma for drug development.
- Achilles Therapeutics: Achilles Therapeutics is a UK-based precision oncology biotech developing targeted immunotherapies guided by tumour-specific signatures. It is comparable as a UK-headquartered, academically-spun precision oncology company with a similar go-to-market motion around biomarker-driven therapies.
Emerging players
- Owkin: Owkin applies AI to patient-level biomedical data to accelerate oncology research and improve treatment decisions, with a pharma partnership GTM. Comparable to Tailor Bio as a techbio/AI precision oncology company leveraging multimodal data and partnerships with pharma rather than selling drugs directly.
Direct peers
- Repare Therapeutics: Repare Therapeutics applies synthetic lethality and CRISPR-enabled target discovery to develop precision oncology drugs. It overlaps with Tailor Bio's approach of using genomic signatures (SNP/HRD) to identify vulnerable patient populations for targeted therapy.
- Tango Therapeutics: Tango Therapeutics uses functional genomics to identify synthetic lethal targets in cancer and develops precision oncology therapeutics. The mechanism-based, biomarker-driven approach to drug discovery closely mirrors Tailor Bio's CIN signature platform.
- Artios Pharma: Artios Pharma develops DDR-targeted oncology drugs exploiting DNA damage response vulnerabilities, an adjacent class of synthetic lethal strategies. It is comparable to Tailor Bio's therapeutic programs targeting CIN-driven cancers via synthetic lethality.
- Volastra Therapeutics: Volastra is a CIN-focused oncology drug discovery company that Tailor Bio is already partnered with for KIF18A inhibitor biomarkers. Both companies target chromosomal instability as the basis for synthetic lethal therapies and companion diagnostics, making them the most direct peer in the CIN niche.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Tailor Bio social profiles
Digital presenceTailor Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tailor Bio leadership team
Management profileNumber of profiles
Profiles15 records
Tailor Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tailor Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tailor Bio
What does Tailor Bio do?
Tailor Bio operates an AI-driven pan-cancer precision medicine platform built on proprietary chromosomal instability (CIN) signature algorithms that decode CIN complexity to identify synthetic lethal therapeutic targets and predict chemotherapy response. The company develops companion diagnostics for patient stratification and advances therapeutic programs targeting CIN-driven cancers across multiple tumor types from a single genomic test compatible with whole-genome sequencing, targeted panels, and cell-free DNA.
Is Tailor Bio a public or private company?
Tailor Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Tailor Bio founded?
Tailor Bio was founded in 2019. It employs 1 to 10 people.
Where is Tailor Bio based?
Tailor Bio is headquartered in London, United Kingdom, in the Europe region.
How does Tailor Bio make money?
Three revenue lines are on record. Companion Diagnostic Licensing & Partnerships are the primary driver. The others are therapeutic Drug Discovery Platform and clinical CIN Test Deployment.
Who are Tailor Bio's main competitors?
Broad incumbents on record are Caris Life Sciences, Guardant Health, Foundation Medicine, Tempus AI and Achilles Therapeutics. Owkin is listed as an emerging player. Direct peers are Repare Therapeutics, Tango Therapeutics, Artios Pharma and Volastra Therapeutics.
Does Tailor Bio have an API?
No public API is recorded for Tailor Bio.
What industry is Tailor Bio in?
Tailor Bio's product category is Precision Oncology Platforms. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine. Its NAICS code is 541714 and its SIC code is 8071.